The idea of robots operating inside the human body has long been associated with science fiction. But recent advances in DNA-based nanotechnology are beginning to translate that vision into early-stage experimental systems, where programmable molecular machines can move, sense, and interact with biological environments.

Researchers are now designing DNA “robots” capable of delivering drugs directly to diseased cells and identifying viral threats within the bloodstream. While these systems remain far from clinical deployment, they represent a shift in how robotics is defined – extending from mechanical systems into the molecular domain.

Reimagining Robotics at the Molecular Scale

Unlike conventional robots built from metal, electronics, and actuators, DNA robots are constructed from strands of nucleic acids that can be folded, connected, and programmed into functional structures. Using techniques inspired by origami, scientists can create rigid joints, flexible linkages, and dynamic components that mimic mechanical systems at a nanoscale.

This approach adapts established principles from traditional robotics – including rigid-body motion and compliant mechanisms – into a biochemical context. The result is a new class of machines that operate not through motors or gears, but through chemical interactions and structural transformations.

Controlling these systems presents a fundamental challenge. At the molecular level, motion is dominated by random thermal fluctuations, known as Brownian motion, which can disrupt precise behavior. To address this, researchers rely on biochemical programming methods such as DNA strand displacement, where specific sequences act as triggers to initiate movement or change configuration.

External signals, including light, magnetic fields, and electric fields, can also be used to guide these nanorobots, providing an additional layer of control in otherwise unpredictable environments.

Medical Applications Remain Experimental

The most immediate interest in DNA robotics lies in medicine, where the ability to operate at cellular or even molecular resolution could enable highly targeted interventions. In experimental settings, DNA robots have been designed to locate specific cell types, release therapeutic payloads, and potentially capture or neutralize viruses.

Such systems could function as “nano-surgeons”, delivering drugs with far greater precision than conventional treatments and reducing side effects associated with systemic therapies. Researchers are also exploring their potential to detect and bind to viral particles, including pathogens similar to COVID-19, as a step toward autonomous diagnostic or therapeutic platforms.

Beyond medicine, DNA robots may also serve as tools for nanoscale manufacturing. By positioning molecules and nanoparticles with sub-nanometer precision, they could enable new forms of computing and materials engineering that are difficult to achieve with existing fabrication techniques.

However, most current systems remain proof-of-concept demonstrations. They typically operate in controlled laboratory conditions and lack the robustness required for real-world biological environments.

From Proof of Concept to Scalable Systems

The transition from experimental prototypes to practical applications presents several challenges. In addition to environmental unpredictability, researchers face limitations in modeling and design. There is currently no comprehensive database of DNA mechanical properties, and simulation tools for predicting nanorobot behavior remain underdeveloped.

Scaling these systems will likely require advances across multiple domains, including bio-manufacturing, materials science, and artificial intelligence. Proposed approaches include the development of standardized DNA component libraries and the use of AI-driven design tools to optimize structures and predict performance.

The broader implication is that robotics may increasingly extend beyond traditional hardware into programmable biological systems. DNA robots, if successfully scaled, could redefine automation at the smallest possible level – enabling machines that operate not in factories or warehouses, but within cells and molecules themselves.

For now, the technology remains in its formative stage. But its trajectory suggests that the next phase of robotics innovation may be less about building larger, more capable machines, and more about engineering systems that can function where conventional robots cannot reach.

News, Robots & Robotics, Science & Tech

The planned public listing of Unitree Robotics marks a turning point for the humanoid robotics sector, which has long been defined by prototypes, research funding, and speculative timelines. By moving toward an initial public offering, the Hangzhou-based company is positioning itself as one of the first large-scale tests of whether humanoid robots can sustain a viable commercial market.

Unitree filed to list on the Shanghai Stock Exchange on March 20, seeking to raise 4.2 billion yuan, or about $610 million, to expand manufacturing and research. The company’s trajectory, from viral demonstrations to profitability within a year, places it at the center of a broader shift in how robotics companies are financed and evaluated.

Profitability Arrives Ahead of Mass Adoption

Unlike many peers, Unitree enters the public markets with profitability already established. The company reported an adjusted net profit of 600 million yuan in 2025, a sharp increase from its first profitable year in 2024. Revenue rose to 1.71 billion yuan from 392 million yuan the previous year, reflecting both volume growth and expanding product adoption.

This distinguishes Unitree from earlier entrants such as UBTech Robotics, which has remained unprofitable despite going public. The contrast highlights a widening gap between companies still operating in development mode and those beginning to scale production.

Even so, the market remains early. More than 100 humanoid robotics companies currently operate in China, according to Counterpoint Research, with consolidation expected as capital markets begin to impose stricter performance expectations. Unitree’s IPO is likely to serve as an early signal of which business models can sustain investor confidence.

From Quadrupeds to Humanoids

Unitree’s growth has been driven in part by a transition from quadruped robots to humanoid systems. The company shipped more than 30,000 quadrupeds between 2022 and 2025, establishing a hardware and supply chain base before scaling humanoid production.

In 2025, it sold 5,500 humanoid robots, which accounted for over half of its core revenue, up from less than 2% two years earlier. The majority of these units were sold to research institutions and educational users, indicating that widespread enterprise deployment remains limited.

The shift reflects a broader industry pattern, in which quadruped platforms have served as an intermediate step toward more complex humanoid systems. These earlier products provide revenue, operational data, and manufacturing experience that can be transferred into humanoid development.

Falling Prices and Vertical Integration

One of the more notable signals in Unitree’s prospectus is the rapid decline in pricing. The average price of its humanoid robots fell from roughly 593,400 yuan in 2023 to 167,600 yuan in 2025, bringing systems closer to a range that could support broader adoption.

At the same time, gross margins improved to nearly 60%, suggesting that cost reductions are being driven by manufacturing efficiencies rather than discounting alone. Unitree attributes this to its strategy of developing and producing key components in-house, reducing reliance on external suppliers.

This combination of falling prices and improving margins remains rare in the humanoid robotics sector, where most companies are still managing high costs and limited production volumes.

However, external dependencies remain. Like many robotics developers, Unitree relies on computing platforms and chips from Nvidia for core processing capabilities, leaving part of its supply chain exposed to geopolitical and trade uncertainties.

A Market Signal for Physical AI

Unitree’s IPO arrives amid intensifying global competition in humanoid robotics. In the United States, Elon Musk has said that Tesla plans to begin retail sales of its Optimus robots by 2027, framing humanoids as a future mass-market product.

At the same time, the concept of “physical AI” – systems that combine machine learning with real-world interaction – is gaining traction across the industry. Unitree’s robots were featured alongside other platforms at a recent conference led by Jensen Huang, underscoring growing alignment between hardware manufacturers and AI infrastructure providers.

Despite this momentum, near-term demand remains concentrated in research, education, and controlled industrial environments. Unitree’s own projections, which include plans to produce tens of thousands of humanoids annually within five years, suggest confidence in scaling, but not necessarily immediate mass adoption.

The company’s public listing will therefore function as more than a financing event. It will offer one of the first measurable indicators of whether investors view humanoid robotics as an emerging industrial category or as a longer-term technological bet.

Business & Markets, News, Robots & Robotics

Chinese robotics firm Ubtech Robotics reported a sharp increase in humanoid robot sales, offering one of the clearest signals yet that the sector is moving from pilot projects to early commercial deployment. The company said it sold more than 1,000 full-size humanoid robots last year, representing a 23-fold increase compared with the previous year.

The surge in sales was accompanied by a significant shift in revenue composition. Humanoid robots accounted for more than 40 percent of total revenue, up from a negligible share the year before. The results highlight how embodied AI systems are beginning to contribute meaningfully to business performance rather than remaining confined to research or demonstration.

The company’s stock rose following the announcement, reflecting investor interest in what is increasingly viewed as a high-growth segment within robotics.

Industrial Deployment Drives Growth

Ubtech’s growth has been driven primarily by the deployment of its Walker S series humanoid robots in industrial environments. These systems are being used across sectors including automotive manufacturing, electronics, semiconductors, and logistics.

The robots are designed to perform tasks such as material handling, sorting, assembly, and inspection, positioning them as flexible alternatives to traditional automation systems. Unlike fixed industrial robots, humanoids can operate in environments built for human workers, reducing the need for infrastructure changes.

This shift from training to deployment marks a turning point. For several years, humanoid robotics companies have focused on developing capabilities and collecting data. Ubtech’s results suggest that at least part of the market is now transitioning toward real-world applications with measurable output.

At the same time, the company continues to expand into non-industrial scenarios, including education, research, and public-facing roles such as event assistance and exhibition guides. These use cases provide additional pathways for adoption, though industrial deployments appear to be driving the majority of revenue growth.

China’s Accelerating Embodied AI Push

Ubtech’s performance reflects a broader trend within China’s robotics ecosystem, where government support, manufacturing capacity, and supply chain integration are enabling rapid scaling.

While revenue from some of the company’s legacy robotics segments declined, the growth in humanoid systems more than offset those losses, contributing to an overall increase in total revenue and an improvement in gross margins. The company also reported a narrowing net loss, suggesting early signs of improving operational efficiency as production scales.

The pace of growth underscores a key dynamic in the global robotics race. Chinese companies are moving quickly to commercialize humanoid systems, leveraging cost advantages and manufacturing expertise to accelerate deployment.

The sharp increase in Ubtech’s humanoid robot sales highlights a broader inflection point for the industry. As systems transition from development to deployment, the focus is shifting toward reliability, scalability, and economic viability.

For Ubtech, the challenge will be sustaining growth while improving profitability in a market that is likely to become increasingly competitive. For the industry, the company’s results provide early evidence that humanoid robots may be moving beyond experimentation and into the first stages of commercial adoption.

Whether that momentum can be maintained will depend on the ability of these systems to deliver consistent value in real-world environments. But for now, the trajectory is clear: embodied AI is beginning to generate tangible business outcomes, not just technical demonstrations.

Business & Markets, News, Robots & Robotics

The humanoid robotics industry may be approaching its first meaningful commercial inflection point, driven not by a single breakthrough but by a rapid decline in prices. New data from manufacturers indicates that average system costs have fallen dramatically over the past two years, reshaping expectations around adoption and market structure.

Reported pricing for some platforms has dropped from roughly $85,000 in 2023 to about $25,000 in 2025, reflecting a broader trend across the sector. While high-end systems still command significantly higher prices, the overall range has expanded, with entry-level humanoids now approaching levels previously associated with industrial equipment rather than research prototypes.

The shift suggests that humanoid robots are beginning to follow the economic trajectory seen in other hardware-driven industries, where scaling production and standardizing components lead to rapid cost compression.

From Experimental Platforms to Manufactured Products

For much of the past decade, humanoid robots existed primarily as research systems, built in small volumes and priced accordingly. Their role was to demonstrate capability rather than deliver consistent operational value.

That dynamic is changing as companies move into early production runs. Standardized components, improved supply chains, and iterative design cycles are reducing costs while increasing reliability. Even companies still developing their platforms are publicly targeting price points in the $20,000 to $30,000 range once manufacturing reaches scale.

This transition marks a critical shift. As humanoids become manufactured products rather than bespoke systems, they enter a different set of economic constraints. Pricing, margins, and return on investment begin to matter as much as technical capability.

A Three-Tier Market Begins to Form

As prices fall, the market is starting to segment into distinct tiers, each defined by a different strategy.

At the high end, premium systems focus on maximum performance, targeting industrial and enterprise environments where reliability and capability justify higher costs. These platforms often exceed $150,000 and emphasize advanced manipulation, safety, and integration.

In the middle, a growing category of “good enough” humanoids is emerging. These systems aim to balance performance with affordability, making them viable for applications such as logistics, warehousing, and light manufacturing. With projected pricing around $20,000 to $30,000, this segment is widely expected to drive the majority of unit volume.

At the lower end, a volume-driven approach is taking shape. Some manufacturers are aggressively reducing costs to accelerate adoption, offering simplified systems at significantly lower price points. This strategy prioritizes scale and rapid iteration, echoing patterns seen in industries such as electric vehicles and solar energy.

Price Compression Creates Strategic Pressure

The rapid decline in prices introduces both opportunity and risk. Lower costs could accelerate adoption in sectors facing labor shortages, where even modest improvements in productivity can justify investment.

At the same time, price compression is likely to strain margins and intensify competition. For companies in the United States and Europe, competing on cost alone may prove difficult, potentially pushing them toward premium positioning strategies that emphasize performance, safety, and integration.

This dynamic mirrors developments in other manufacturing sectors, where different regions specialize in either high-end engineering or cost-efficient production. Whether humanoid robotics follows a similar path remains uncertain, given that large-scale demand has yet to fully materialize.

The emergence of tiered pricing signals that humanoid robotics is entering a more mature phase. The industry is moving beyond demonstrations toward real economic constraints, where success depends not only on what robots can do, but on whether they can do it at a cost that makes sense.

Falling prices are a necessary step toward widespread deployment, but they do not guarantee it. The next phase will test whether humanoid robots can deliver consistent performance in real-world environments and generate measurable returns.

If they can, the current decline in prices could unlock large-scale adoption across industries. If not, it may instead mark a transition from early optimism to a more selective and competitive market.

Business & Markets, News, Robots & Robotics